October 4, 2020
Yesterday, Friday, Harrison County had 5 new cases, Gregg 8, and Smith 23.
Smith County schools see increase in COVID-19, most among staff, students in grades 7-12
DOES AZITHROMYCIN HELP COVID (Z-PACK)
J. Harris: As I understand this and other similar articles:1. No help in sever hospitalized cases with or without hydroxychloroquine2. Does it help if used very early in the disease? ‘UNKNOWN3. If I got sick and had a Z Pack, would I take it early even for mild symptoms? Probably.4. Would I panic if I got sick and didn’t have a Z Pack? No. But I’d talk to my doctor about it, especially since I am still fortunate enough to have a personal physician who I know and trust and who knows my medical history and who is associated with Christus.
HOW TO SIGN UP OF JOHNS HOPKINS MAILOUTS
(JHarris: Their free emails concerning COVID and medicine with several weekly publications and summaries in several categories are the best source of current information that I have found. I try and pick and choose and “translate” the information that I think is most pertinent for our local and area situation, but readers might want to read in more detail. Now, as Hopkins continues to expand and improve, I less often dig around in the multitude of various journals for bits of truth. If you like charts, they have the best.)
FROM JOHNS HOPKINS:1. FOR THE LAST TIME, HYDROXYCHLOROQUINE PROPHYLAXIS DOES NOT WORK:Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers (JAMA Network) Among hospital-based HCWs at high risk of exposure to SARS-CoV-2, hydroxychloroquine, 600 mg, daily, for 8 weeks did not reduce the incidence of SARS-CoV-2 infection compared with placebo. Our findings are consistent with what is to our knowledge the only other randomized COVID-19 prophylaxis trial published to date.
Risk of COVID-19 During Air Travel
2. AUG 20: A promising new coronavirus cure just failed in its Phase 3 trial A potential coronavirus cure has failed to meet the primary goals of its Phase 3 trial despite the promise the drug has shown elsewhere.
Tocilizumab did not improve the clinical status of COVID-19 patients and did not reduce patient mortality in Roche’s Phase 3 testing.
The drug still holds potential and will continue to be studied. Several other researchers have been working with tocilizumab and other interleukin-6 inhibitors in COVID-19 therapies, and have seen some success.
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.